

*Unofficial English translation – For convenience purposes only*

**Biotalys**  
Limited liability company  
Buchtenstraat 11, 9051 Ghent  
0508.931.185  
(the *Company*)

---

**Special report of the board of directors of the Company (the *Board of Directors*) pursuant to Article 7:198 in conjunction with Articles 7:179, 7:191 and 7:193 of the Belgian Code of Companies and Associations regarding the capital increase of the Company**

---

## **1. INTRODUCTION**

A special report has been prepared by the Board of Directors of the Company on 5 May 2026 pursuant to Article 7:198 in conjunction with Articles 7:179, 7:191 and 7:193 of the Belgian Code of Companies and Associations (the *BCCA*) in the context of the proposed increase of capital of the Company by way of contribution in cash under the authorised capital for an amount of EUR 12,050,000.00 (including issue premium) through the issuance of 7,875,811 new shares with, in the interest of the Company, cancellation of the statutory preferential right of the existing shareholders of the Company in favour of certain specified persons who are not members of the Company's personnel (the *Capital Increase*) (the *Initial Report*).

This special report has now been prepared by the Board of Directors to correct the Initial Report which contained a clerical error regarding the identity of two of the investors subscribing to the Capital Increase in favour of whom the preferential subscription right of the existing shareholders of the Company would be cancelled. The Initial Report stated that one investor would be ASR Nederland N.V., with registered office address at Archimedeslaan 10, box 2072, 3584 BA Utrecht, The Netherlands, with company number 30070695, but the entity that will actually subscribe to the Capital Increase will be an affiliate of such entity, namely ASR Vermogensbeheer N.V., with registered office address at Archimedeslaan 10, box 2072, 3584 BA Utrecht, The Netherlands, with company number 30227237. The Initial Report also stated that one investor would be Sofinnova Partners S.A.S., with registered office address at 7-11, Boulevard Haussmann, 75009 Paris, France, with company number 413 388 596, but the entity that will actually subscribe to the Capital Increase will be Sofinnova Industrial Biotech I, represented by Sofinnova Partners S.A.S., with registered office address at 7-11, Boulevard Haussmann, 75009 Paris, France, with company number 413 388 596.

The Capital Increase will take place pursuant to a placement by, and the new shares will be issued in favour of the following existing shareholders of the Company or persons connected with existing shareholders of the Company:

- (i) Ackermans & van Haaren, with registered office address at Begijnenvest 113, 2000 Antwerpen, with company number 0404.616.494 (*AvH*),
- (ii) Agri Investment Fund BV, with registered office address at Diestsevest 32, box 5b, 3000 Leuven, with company number 0893.885.781 (*AIF*),
- (iii) ASR Vermogensbeheer N.V., with registered office address at Archimedeslaan 10, box 2072, 3584 BA Utrecht, The Netherlands, with company number 30227237 (*ASR*),

*Unofficial English translation – For convenience purposes only*

- (iv) FPIM NV, with registered office address at Louizalaan 32, box 4, 1050 Brussels, with company number 0253.445.063 (**FPIM**),
- (v) GIMV NV, with registered office address at Karel Oomsstraat 37, 2018 Antwerp, with company number 0220.324.117 (**GIMV**),
- (vi) PMV NV, with registered office address at Oude Graanmarkt 63, 1000 Brussels, with company number 0455.777.660 (**PMV**),
- (vii) Sofinnova Industrial Biotech I, represented by Sofinnova Partners S.A.S., with registered office address at 7-11, Boulevard Haussmann, 75009 Paris, France, with company number 413 388 596 (**Sofinnova**),
- (viii) Dokter Stijn Van de Velde BV, with registered office address at Muinkkaai 51, box C, 9000 Ghent, with company number 0894.421.063 (**SVDV**), and
- (ix) VIB VZW, with registered office at Suzanne Tassierstraat 1, 9052 Zwijnaarde, with company number 0456.343.923 (**VIB**),

(hereinafter together the **Beneficiaries**).

In accordance with Article 7:198 *in conjunction with* Articles 7:179, 7:191 and 7:193 of the BCCA, the Board of Directors has prepared this report on the Capital Increase, in which, in particular, it justifies in detail the transaction and the issue price in the corporate interest, taking into account, in particular, the financial situation of the Company, the identity of the Beneficiaries, the nature and extent of their contribution, and it describes and justifies the consequences of the transaction, including the cancellation of the preferential subscription rights, on the shareholders' ownership and membership rights and expressly describes and justifies the reasons for the limitation or cancellation of the preferential subscription rights.

This special report should be read together with the report prepared, as far as needed and applicable, by the Company's statutory auditor, Deloitte Bedrijfsrevisoren BV, a company with limited liability organised and existing under the laws of Belgium, with registered office at Gateway Building, Luchthaven Brussel Nationaal 1 J, 1930 Zaventem, Belgium, represented by Mr Pieter-Jan Van Durme, in accordance with Article 7:198 *in conjunction with* Articles 7:179, 7:191 and 7:193 of the BCCA with respect to the Capital Increase.

## **2. DESCRIPTION OF THE CAPITAL INCREASE**

### **2.1 Notes to authorised capital**

On 23 April 2024, the extraordinary general meeting of the Company granted an authorisation to the Board of Directors under the authorised capital for a period of five years and set the amount of the authorised capital under that general authorisation at 100% of the capital, i.e. EUR 4,755,005.78. This decision was published in the Annexes to the Belgian Official Gazette on 26 April 2024. Accordingly, Article 6 (*Authorised Capital*) of the Company's Articles of Association reads as follows:

*§1. The board of directors may increase the company's capital on one or more occasions by a (cumulative) amount not exceeding four million seven hundred and fifty-five thousand and five euros and seventy-eight cents (€4,755,005.78). This authorisation may be renewed in accordance with the applicable legal provisions. The board of directors may exercise this authorisation for a period of five (5) years from*

*Unofficial English translation – For convenience purposes only*

*the date of publication in the Annexes to the Belgian Official Gazette of the authorisation approved by the extraordinary general meeting of 23 April 2024.*

*§The capital increases which may be decided pursuant to this authorisation shall be carried out in accordance with the modalities to be determined by the Board of Directors and may be realised by means of contributions in cash or in kind or by conversion of reserves into capital, whether or not available or unavailable for distribution and issue premiums, with or without the issuance of new shares and with or without payment of an issue premium.*

*The board of directors may also use this authorisation to issue convertible bonds, subscription rights or bonds to which subscription rights or other movable securities are attached, or other securities.*

*When using its authorisation within the framework of the authorised capital, the board of directors may, in the interest of the company, within the limits and in accordance with the conditions prescribed by the Companies and Associations Code, limit or cancel the shareholders' preferential right. This restriction or cancellation may also be done in favour of members of the personnel of the company or its subsidiaries or in favour of one or more certain persons other than members of the personnel of the company or its subsidiaries.*

*§3. If, on the occasion of a capital increase decided on within the framework of the authorised capital, an issue premium is paid, it shall be recorded in the account "Issue premiums", which shall constitute a guarantee for third parties to the same extent as the company's capital and which, subject to the possibility of converting this reserve into capital, may only be disposed of in accordance with the conditions laid down by the Companies and Associations Code for amendments to the articles of association.*

*§4. The board of directors is hereby expressly authorised to proceed with a capital increase in any form, including but not limited to a capital increase accompanied by a limitation or cancellation of preferential subscription rights, even after the company receives the communication from the Financial Services and Markets Authority (FSMA) that it has been notified of a public takeover bid for the company's shares. This authorisation is valid in relation to public takeover bids for which the company receives the aforementioned notification not more than three years after 23 April 2024. This authorisation may be renewed for an additional period of three years by resolution of the general meeting, which deliberates and decides in accordance with the applicable provisions. The capital increases decided under this authorisation will be allocated to the remaining part of the authorised capital referred to in the first paragraph.*

*§5. The board of directors shall be authorised, with the possibility of substitution, to amend the articles of association after any capital increase, which has come about within the limits of the authorised capital, in order to bring them into line with the new capital and share situation.*

The report pursuant to Article 7:199 of the BCCA explained that the Board of Directors intended to make use of its authorisation under the authorised capital in circumstances where, in the interest of the Company, convening a general meeting of shareholders would not be desirable or expedient, with such a situation arising, for example, where:

*Unofficial English translation – For convenience purposes only*

- a) it proves necessary to respond quickly to market opportunities;
- b) there is a need for financing where market conditions do not lend themselves to an issuance to all shareholders;
- c) a prior convocation of a general shareholders' meeting would result in too early an announcement of the transaction in question, which could be to the Company's disadvantage;
- d) the costs associated with convening a general meeting of shareholders are disproportionate to the amount of the proposed capital increase; or
- e) because of the urgency of the situation, it appears that implementing a capital increase in accordance with the authorised capital procedure is necessary in the interest of the Company.

The same report explained that the Board could use its authorisation under the authorised capital, among other things:

- a) for the purpose of strengthening the capital or equity of the Company including investments by one or more specified persons (whether or not current shareholders) or cornerstone investors;
- b) to finance the Company's business activities or new business initiatives;
- c) to finance or achieve (in whole or in part) acquisitions or acquisitions of companies, businesses or assets, corporate partnerships, in-licensing transactions or other forms of mergers, partnerships or strategic alliances;
- d) to create or honour (from time to time) share-based compensation plans for members of staff, independent consultants and other service providers of the Company and/or its subsidiaries (e.g. by issuing share subscription rights or issuing share units);
- e) to avert an unwanted public takeover bid for the Company's securities; and/or
- f) for other general working capital needs.

On the date hereof, the Board of Directors has used that authority twice i.e. in the framework of the private placement of 5,300,352 new shares that closed on 16 October 2024 and resulted in a capital increase of EUR 783,749.72 and in connection with the issue of the underlying shares to share units entered into by independent directors on 22 July 2025, whereby a total of 6,083 new shares were issued and the capital was increased by EUR 899.48. At present, the Board of Directors therefore still has an authorized capital of EUR 3,970,356.58 at its disposal.

## **2.2 Structure of the Capital Increase and cancellation of existing shareholders' preferential rights in favour of the Beneficiaries**

In accordance with Article 6 of the Company's Articles of Association, the Board of Directors intends to increase the Company's capital under the authorised capital by a cash contribution in the amount of EUR 12,050,000.00 (including issue premium) against the issuance of 7,875,811 new shares. As a result of the Capital Increase, the Company's capital will increase with an amount of EUR 1,164,576.36 to EUR 6,719,757.41 (excluding issue premium) and 45,444,456 shares will have been issued. The amount of the capital increase of EUR 1,164,576.36 takes

*Unofficial English translation – For convenience purposes only*

into account the fractional value of a share of (rounded) EUR 0.1479. The remainder of the issue price i.e. EUR 10,885,423.64 will be booked as unavailable issue premium.

Pursuant to Article 6 of the Company's Articles of Association, the Board of Directors is authorised, in accordance with the BCCA, as amended from time to time, when it increases the capital, to limit or cancel the preferential subscription right, including for the benefit of one or more specified persons (whether or not employees of the Company or its subsidiaries). In light of the foregoing, the Board of Directors proposes, in accordance with Article 6 of the Company's Articles of Association and Article 7:193 of the BCCA, to cancel the preferential subscription right in favour of the Beneficiaries.

In the context of the Capital Increase and as a result of the cancellation of the statutory preferential rights, the Beneficiaries will subscribe to the following new shares:

- (i) AvH will subscribe to 1,633,986 new shares,
- (ii) AIF will subscribe to 2,156,862 new shares,
- (iii) ASR will subscribe to 1,633,986 new shares,
- (iv) FPIM will subscribe to 326,797 new shares,
- (v) GIMV will subscribe to 980,392 new shares,
- (vi) PMV will subscribe to 261,437 new shares,
- (vii) Sofinnova will subscribe to 65,359 new shares,
- (viii) SVDV will subscribe to 653,594 new shares, and
- (ix) VIB will subscribe to 163,398 new shares.

### **2.3 Issue price of the new shares**

The issue price is the result of negotiations and/or discussions between the Company and the Beneficiaries with reference to relevant stock market prices of the Company's shares on Euronext Brussels..

The issue price for the new shares to be issued in the context of the Capital Increase is EUR 1.53. This issue price equals the volume weighted average price of the Company's share on Euronext Brussels during the period of 30 days from (and including) 1 April 2026 till (and including) 30 April 2026 with a discount of 40%.

This issue price is (rounded) 48.66% lower than the closing price of the Company's shares on Euronext Brussels on 4 May 2026. The issue price of the new shares is EUR 1.53 per new share amounting to a total issue price of EUR 12,050,000.00 of which an amount of EUR 1,164,576.36 will be allocated to the capital of the Company (taking into account a fractional value of the shares of EUR 0.1479 (rounded) and the remainder, i.e. EUR 10,885,423.64, will be booked as unavailable issue premium). This issue premium will be recorded on the liability side of the Company's balance sheet as net equity. The account in which the issue premiums will be booked will, like the capital, serve as a guarantee for third parties and, subject to the possibility of capitalisation of these reserves, can only be reduced based on a valid resolution of the general meeting of shareholders, passed in the manner required for an amendment to the Company's Articles of Association.

*Unofficial English translation – For convenience purposes only*

## **2.4 Admission to trading of the new shares**

The new shares will have to be admitted to trading on the regulated market of Euronext Brussels. To this end, the Company will file the necessary documents, as required by applicable regulations, to enable an admission to trading on the regulated market of Euronext Brussels after the issuance of the new shares (see also section 2.6).

## **2.5 The rights attached to the new shares**

As at the date of this report, all shares of the Company entitle their holders to one vote and all shares of the Company share equally in the profits of the Company in the same proportion. In addition, all shares of the Company are equally entitled to preferential rights to capital increases in cash (to the extent not cancelled or restricted in accordance with statutory provisions), and are entitled to an equal share in the net proceeds following any distribution.

The new shares to be issued will have the same rights and benefits as, and will in all respects have the same (*pari passu*) rank, including entitlement to dividends and distributions for the full current financial year and all future financial years, as the current and outstanding shares of the Company at the time of their issuance and will be entitled to distributions for which the relevant record date or maturity date is on or after the date of issuance of the new shares.

## **2.6 No prospectus**

In accordance with Article 1(5)(a) of Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC (as amended or superseded) (the ***Prospectus Regulation***), no prospectus is required for the admission to trading of the new shares as the relevant new shares, over a 12-month period, represent less than 30% of the number of shares of the Company already admitted to trading.

As the new shares are offered only to the Beneficiaries and there has been no "public offering" within the meaning of the Prospectus Regulation, no issue prospectus is required.

## **3. JUSTIFICATION**

### **3.1 Justification of the envisaged Capital Increase and cancellation of preferential rights**

The Board believes that the Capital Increase is in the best interest of the Company because, if completed, the transaction will support the Company's equity position and working capital and the Company's going concern taking also into account that without the Capital Increase the Company expects its cash runway to expire end of May 2026. The proposed Capital Increase will allow the Company to further pursue its refocused strategic goals as these have been announced by the Company in its press release dated 9 February 2026 and potentially reach further milestones in that respect which could be a stepstone to attract further equity financing or debt financing.

In particular, the Company currently intends to use the net proceeds:

- To fund the progress of the Company's most advanced biofungicide programs – EVOCA NG and BioFun-6, including through further process development, field trials and the conducting of regulatory processes;

*Unofficial English translation – For convenience purposes only*

- To fund the ongoing platform development and intellectual property capture to maintain competitiveness and increase the efficiency of Biotalys' 2.0 AGROBODY Foundry™ platform;
- To support the retention of key talent; and
- For general business purposes.

The investment of the Beneficiaries demonstrates their support of the Company's business and strategy and allows the Company to strengthen its relationship with these investors, which may enable the Company to further strengthen its image with investors, which is in the interest of the further development of the Company's business and any future capital market transactions.

Indeed, the Beneficiaries are all investors with a good reputation which have showed their support for the Company in the past, as all of these investors are current shareholders of the Company or persons connected with current shareholders of the Company, some of which even since the incorporation of the Company.

The Board of Directors proposes to cancel the preferential right of the Company's shareholders in favour of the Beneficiaries. The cancellation of the preferential right in favour of the Beneficiaries allows the Company to raise a significant amount of funds through an accelerated process, without high transaction risk, to further strengthen its equity and working capital, thereby, among other things, freeing up space for the Company to fund its operations. These activities require further investment and funding and, if successful, the Company could use the net proceeds of the proposed Capital Increase for these activities.

Second, the Capital Increase, through the participation of the Beneficiaries, may improve the stability of the Company's shareholder structure. This is in the interest of both the Company and the Company's shareholders.

Third, proceeding at this stage to raise funds through a public issue with or without preferential rights would be difficult to achieve. A public issue is not only very costly for the Company, it also requires significantly longer preparation time and favourable market conditions while the ability to raise capital may change during that period. Although the documentary requirements to launch public offerings have been reduced through changes in the prospectus regulation, in practice, this simplified regulatory framework seems not to be available for companies with a risk profile like the Company. Hence, reverting to a public fundraising requires more time and costs. In addition, public fundraising is, in general but in particular for companies with a risk profile like the Company, also accompanied by uncertainty as to whether, in such a longer and more expensive process, a capital increase can ultimately be realised on acceptable terms. In contrast, the Capital Increase subscribed to by the Beneficiaries enables the Company to raise new funds quickly and cost-effectively.

Fourth, it is also noted that due to macroeconomic factors such as the geopolitical situation in Eastern Europe and the Middle East, capital markets have been extremely volatile and investors are reluctant to invest in pre-commercial and revenue (biotech) companies such as the Company. Consequently, the Capital Increase, if successful, gives the Company the opportunity, and it is in the latter's interest, to raise new funds quickly and efficiently in these circumstances.

For all these reasons, the Board of Directors is of the opinion that the proposed Capital Increase, even with the cancellation of the preferential subscription right in favour of the Beneficiaries and notwithstanding the resulting shareholder dilution, is in the interest of both the Company

*Unofficial English translation – For convenience purposes only*

and its existing shareholders, as it may enable the Company to raise the new funds required to further implement its strategy in a rapid and cost-effective manner.

### **3.2 Justification of the issue price of the new shares**

The issue price is determined by the Board of Directors based on negotiations and/or discussions with the Beneficiaries.

The issue price for the new shares to be issued pursuant to the Capital Increase is (rounded) 48.66% lower than the closing price of the Company's shares on Euronext Brussels on 4 May 2026.

The issue price for the new shares to be issued in the context of the Capital Increase is EUR 1.53. This issue price equals the volume weighted average price of the Company's share on Euronext Brussels during the period of 30 days from (and including) 1 April 2026 till (and including) 30 April 2026 with a discount of 40%.

A discount to the share price is not uncommon in private placements by listed companies and the current level reflects, inter alia, the risk profile of the Company including the limited remaining cash runway of the Company, the reluctance of investors, as evidenced in many discussions, to invest in companies with a risk profile like the Company inter alia driven by the geopolitical situation, the uncertainties around the regulatory timelines for the approval of the Company's product candidates and the related uncertainties regarding the timing for the commercialisation of the Company's product candidates, as well as the Company's limited market capitalisation and daily trading volume.

Furthermore, the issue price also takes into account that each of the Beneficiaries agreed to a lock-up period of 3 months following the date on which the new shares will be issued.

Based on the above, the Board acknowledges that the issue price is determined based on objective and market-based methods through a competitive and arm's length process with different relevant investors and thus reflects a fair and market-conform value which is the same for all the Beneficiaries.

## **4. EFFECTS OF THE CAPITAL INCREASE AND CANCELLATION OF PREFERENTIAL SUBSCRIPTION RIGHTS IN FAVOR OF THE BENEFICIARIES ON THE FINANCIAL AND MEMBERSHIP RIGHTS OF EXISTING SHAREHOLDERS**

### **4.1 Introductory remarks**

The effects of the Capital Increase and the cancellation of the preferential right in favour of one or more specified persons who are not personnel of the Company on the shareholders' financial and membership rights pursuant to Articles 7:179, 7:191 and 7:193 of the BCCA are discussed in more detail below.

The following parameters and assumptions were used to illustrate some of the financial implications and in particular the dilution to shareholders:

- (a) On the date of this report, the capital of the Company amounts to EUR 5,555,181.05, represented by 37,568,645 shares without nominal value, each representing the same fraction of the capital, i.e. EUR 0.1479 (rounded). The capital is fully and unconditionally subscribed and paid up;

*Unofficial English translation – For convenience purposes only*

- (b) As at the date of this report, subscription rights exist under the Company's existing incentive plans for employees and management and share units granted to the independent directors which, upon exercise of all subscription rights granted and conversion of all share units, would give rise to issuance of 1,816,514 new shares which would represent additional dilution to shareholders; and
- (c) The issue price of the new shares to be issued under the Capital Increase (determined as set forth in section 2.3 of this report), is EUR 1.53 per new share (representing a discount of (rounded) 48.66% to the closing price of the Company's shares on Euronext Brussels on 4 May 2026 and a discount of 40% to the volume weighted average price of the Company's shares on Euronext Brussels during the period of 30 days from (and including) 1 April 2026 to (and including) 30 April 2026.

#### **4.2 Evolution of the Company's capital and rights attached to shares**

Each share of the Company currently represents an equal portion of the capital of the Company and entitles it to one vote. The issuance of new shares in connection with the Capital Increase will result in a dilution of the shareholders of the Company and of the relative voting rights attached to each share in the Company, as the current shareholders do not have the right to participate in the Capital Increase (except for the Beneficiaries who are already a shareholder).

The dilution with regard to voting rights applies *mutatis mutandis* to the participation of each share in profits and liquidation proceeds and other rights attached to the Company's shares, such as the statutory preferential right in the event of a capital increase in cash by issuing new shares or in the event of the issuance of new subscription rights or convertible bonds.

More specifically, prior to the Capital Increase, each share of the Company shall share equally in the profits and liquidation proceeds of the Company and each shareholder shall have a statutory preferential right in case of a capital increase in cash or in case of the issuance of new subscription rights or convertible bonds. Upon issuance of the new shares pursuant to the Capital Increase, the new shares to be issued will have the same rights and benefits as, and be of equal rank in all respects with, the current and outstanding shares of the Company at the time of their issuance and delivery, and will be entitled to distributions for which the relevant record date or maturity date falls on or after the date of issuance and delivery of the shares. As a result (and to the extent that the new shares are issued and subscribed for), the participation by shareholders in the profits and liquidation proceeds of the Company and the statutory preferential right in the event of a cash capital increase will be diluted accordingly.

The evolution of the Company's capital and number of voting shares as a result of the proposed Capital Increase is simulated below.

The table below shows the evolution of the number of outstanding shares, assuming 7,875,811 new shares to be issued under the Capital Increase.

For the calculation of the dilution effect the subscription by the Beneficiaries as existing shareholders or persons connected with existing shareholders for the new shares is not included (maximum dilution).

Unofficial English translation – For convenience purposes only

**Evolution of the number of outstanding shares**

|   | <u>Issue price</u><br><u>EUR 1.53 per new share</u> |
|---|---|
| <b>Number of shares outstanding before the Capital Increase</b>               |   |
| (A) Shares outstanding .....  | 37,568,645  |
| <b>Capital increase</b>   |   |
| (B) New number of shares to be issued under the Capital Increase              | 7,875,811   |
| <b>Number of shares outstanding after the Capital Increase</b>                |   |
| (C) Total number of shares outstanding after the Capital Increase (A+B) ..... | 45,444,456  |
| (D) Dilution under the Capital Increase (B/C).....                            | 17.33% <sup>1</sup>                                 |

The table below shows the impact of the Capital Increase, on the evolution of the capital. The issue price is recorded as capital to the extent of the current fractional value of the existing shares (rounded EUR 0.1479), with the balance per new share to be recorded as unavailable share premium.

**Evolution of capital**

|  | <u>Issue price</u><br><u>EUR 1.53 per new share</u> |
|--|---|
| <b>Capital before the Capital Increase</b>                       |   |
| (A) Capital (in EUR) .....                                       | 5,555,181.05  |
| (B) Shares outstanding .....                                     | 37,568,645  |
| (C) Fractional value (in EUR, rounded) .....                     | 0.1479  |
| <b>Capital increase</b>  |   |
| (D) New number of shares to be issued under the Capital Increase | 7,875,811   |
| (E) Increase in capital (in EUR).....                            | 1,164,576.36  |
| <b>Capital after the Capital Increase</b>                        |   |
| (F) Capital (in EUR, rounded) (A+E).....                         | 6,719,757.41  |
| (G) Shares outstanding (B+D) .....                               | 45,444,456  |
| (H) Fractional value (in EUR, rounded) (F/G).....                | 0.1479  |

<sup>1</sup> On a fully basis, in case of exercise of all outstanding subscription rights and conversion of all outstanding share units, which would give rise to the issuance of 1,816,514 new shares, the dilution under the Capital Increase would be 16.66%.

*Unofficial English translation – For convenience purposes only***4.3 Impact on the equity of the Company's shares**

The evolution of the Company's consolidated equity as a result of the Capital Increase is simulated below.

The simulation is based on the following elements:

- The Company's statutory financial statements for the financial year ended 31 December 2025 (which were prepared in accordance with the accounting reference system applicable in Belgium). The Company's equity position as of 31 December 2025 was EUR 9,873,347 or (rounded) EUR 0.2628 per share (based on 37,568,645 shares outstanding as of 31 December 2025). For further information on the Company's equity position as at the aforementioned date, please refer to the statutory financial statements for the financial year 2025, which are available on the Company's website.
- The consolidated financial statements of the Company for the financial year ended 31 December 2025 (which were prepared in accordance with IFRS as approved in accordance with Regulation (EC) 1606/2000). The Company's consolidated equity as of 31 December 2025 was EUR 12,103,157 or EUR 0.3222 per share (based on 37,568,645 shares outstanding as of 31 December 2025). For more information on the Company's consolidated equity position as at the aforementioned date, please refer to the consolidated financial statements for the financial year 2025, which are available on the Company's website.
- The simulation does not take into account any changes in consolidated equity since 31 December 2025.
- Upon issue of new shares in the context of the Capital Increase, the amount of the subscription price of the new shares will be allocated to equity (in the form of capital and, if applicable, share premium). The amount that will be recorded as capital will, per share, be at most equal to the amount of the fractional value of the Company's shares (currently rounded at EUR 0.1479 per share). The balance will be recorded as issue premium.

Based on the assumptions set out above, as a result of the Capital Increase, the equity of the Company on a standalone and consolidated basis would be increased as shown below:

**Evolution of standalone equity**

|  | <u>Issue price</u><br><u>EUR 1.53 per new</u><br><u>share</u> |
|--|---|
| <b>Equity for FY 2025</b>  |   |
| (A) Shareholders' equity (in EUR, rounded) .....                 | 9,873,347   |
| (B) Shares outstanding .....                                     | 37,568,645  |
| (C) Shareholders' equity per share (in EUR, rounded) (A/B)       | 0.2628  |
| <b>Capital increase</b>  |   |
| (D) New number of shares to be issued under the Capital Increase | 7,875,811   |
| (E) Increase in equity (in EUR) .....                            | 12,050,000.00   |

*Unofficial English translation – For convenience purposes only*

|   | <u>Issue price</u>            |
|---|-------------------------------|
|   | <u>EUR 1.53 per new share</u> |
| <b>Equity for FY 2025 after the Capital Increase</b>  |                               |
| (F) Shareholders' equity (in EUR, rounded) (A+E)..... | 21,923,347.00                 |
| (G) Shares outstanding (B+D) .....                    | 45,444,456                    |
| (H) Equity per share (in EUR, rounded) (F/G) .....    | 0.4824                        |

**Evolution of consolidated equity**

|   | <u>Issue price</u>            |
|---|-------------------------------|
|   | <u>EUR 1.53 per new share</u> |
| <b>Consolidated equity for FY 2025</b>                            |                               |
| (A) Shareholders' equity (in EUR, rounded).....                   | 12,103,157                    |
| (B) Shares outstanding .....                                      | 37,568,645                    |
| (C) Shareholders' equity per share (in EUR, rounded) (A/B)        | 0.3222                        |
| <b>Capital increase</b>   |                               |
| (D) New number of shares to be issued under the Capital Increase  | 7,875,811                     |
| (E) Increase in equity (in EUR) .....                             | 12,050,000.00                 |
| <b>Consolidated equity for FY 2025 after the Capital Increase</b> |                               |
| (F) Shareholders' equity (in EUR, rounded) (A+E).....             | 24,153,157.00                 |
| (G) Shares outstanding (B+D) .....                                | 45,444,456                    |
| (H) Shareholders' equity per share (in EUR, rounded) (F/G)        | 0.5315                        |

The above table shows that, from a purely accounting perspective, the Capital Increase will result in an increase of the amount each share represents in the Company's consolidated equity.

**4.4 Financial dilution of existing shareholders**

The evolution of market capitalisation as a result of the proposed Capital Increase is simulated below.

The table below shows the impact of the Capital Increase (assuming 7,875,811 new shares and a capital increase amount of EUR 12,050,000.00 (including issue premium)) on the market capitalisation and the resulting financial dilution at the issue price of EUR 1.53.

As at 4 May 2026 the market capitalisation of the Company was EUR 111,954,562.10, based on a closing price of EUR 2.98 per share. Assuming that, after the Capital Increase, the market capitalisation increases solely with the funds raised based on the parameters set out above, the new market capitalisation will be EUR 2.73 per share (rounded).

This would represent a (theoretical) dilution of 8.43% per share at an issue price of EUR 1.53.

*Unofficial English translation – For convenience purposes only***Evolution of the market capitalisation and financial dilution**

|  | <u>Issue price</u><br><u>EUR 1.53 per new</u><br><u>share</u> |
|--|---|
| <b>Market capitalisation before the Capital Increase</b>                 |   |
| (A) Market capitalisation (in EUR) .....                                 | 111,954,562.10  |
| (B) Shares outstanding .....   | 37,568,645  |
| (C) Market capitalisation per share (in EUR, rounded) (A/B)<br>.....     | 2.9800  |
| <b>Capital increase</b>  |   |
| (D) New number of shares to be issued under the Capital Increase         | 7,875,811   |
| (E) Increase in market capitalisation (in EUR) (D* issue price)<br>..... | 12,049,990.83   |
| <b>Market capitalisation after the Capital Increase</b>                  |   |
| (F) Market capitalisation (in EUR) (A+E) .....                           | 124,004,552.93  |
| (G) Shares outstanding (B+D) .....                                       | 45,444,456  |
| (H) Market capitalisation per share (in EUR, rounded) (F/G)<br>.....     | 2.7287  |
| (I) Financial dilution (in %) ( $+\frac{C-H}{C}$ ) ..                    | 8.43%   |

**4.5 Report of the statutory auditor of the Company**

The Board also refers to the report prepared by the Company's statutory auditor in this regard.

\* \* \*

*Unofficial English translation – For convenience purposes only*

Done on 19 May 2026,

On behalf of the Board of Directors,

Signed by:



996378E67329458...  
Simon Moroney

Chairman of the Board

Signed by:



DEA5D503C4D744C...  
Toni Bucci

Director